eMBR Genomics
Private Company
Funding information not available
Overview
Founded in 2021 and based in Cambridge, Massachusetts, eMBR Genomics is an early-stage biotech focused on advancing in vivo CRISPR gene editing. The company's core innovation lies in its proprietary delivery platforms, which are designed to overcome the significant challenge of safely and efficiently targeting therapeutic editors to specific tissues and cell types. While still in a pre-clinical, pre-revenue stage, eMBR aims to build a pipeline of genomic medicines for monogenic diseases with high unmet need. Its success hinges on validating its delivery technology and translating its research into clinical candidates.
Technology Platform
Proprietary delivery technologies for in vivo CRISPR-based gene editing, designed to target specific tissues and cell types safely and efficiently.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
eMBR competes in the crowded and rapidly advancing field of gene editing delivery, facing competition from large caps (e.g., CRISPR Therapeutics, Intellia Therapeutics, Beam Therapeutics), other platform startups, and academic institutions. Differentiation requires demonstrating superior targeting, safety, or payload capacity.